| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 22,700 | 22,740 | 12:45 | |
| 22,700 | 22,740 | 12:45 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 22,930 | 1.842 | |||
| 22,920 | 1.273 | |||
| 22,910 | 449 | |||
| 22,900 | 325 | |||
| 22,890 | 1.000 | |||
| 22,870 | 273 | |||
| 22,860 | 204 | |||
| 22,850 | 2.000 | |||
| 22,840 | 2.000 | |||
| 22,830 | 2.500 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/gs71.htm [/URL] | ||||
| 527 | 22,790 | |||
| 2.000 | 22,780 | |||
| 2.000 | 22,770 | |||
| 2.204 | 22,760 | |||
| 900 | 22,750 | |||
| 6.471 | 22,740 | |||
| 1.273 | 22,730 | |||
| 8.051 | 22,710 | |||
| 1.771 | 22,700 | |||
| 273 | 22,690 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 25.470 | 0,466 | 11.866 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | -0,220 -0,95 % | 3.691 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:30 | JEFFERIES stuft GSK auf 'Hold' | 305 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Jefferies hat GSK anlässlich der vom Analysehaus ausgerichteten "Global Healthcare Conference" in London mit einem Kursziel von 2100 Pence auf "Hold" belassen. David Redfern... ► Artikel lesen | |
| 09:46 | GSK auf Jefferies Global Healthcare Conference: Wachstumsstrategie im Angesicht der Patentklippe | 7 | Investing.com Deutsch | ||
| Fr | GSK wins positive CHMP opinion for Bexsero meningitis B booster | 9 | Sharecast | ||
| GSK Aktie jetzt für 0€ handeln | |||||
| Fr | GSK Announces Positive CHMP Opinion For Meningitis B Booster | 404 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK plc (GSK, GSK.L) announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended updating the Bexsero label... ► Artikel lesen | |
| Fr | GSK PLC - Bexsero booster receives positive CHMP opinion | 3 | RNS |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 03:58 | Novartis Pharma AG: Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR) | GlobeNewswire (Europe) | Cosentyx (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹Approval marks 11th US indication for Cosentyx, building on its decade-long... ► Artikel lesen | |
| Mo | F. Hoffmann-La Roche Ltd: FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer | GlobeNewswire (Europe) | Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III trial... ► Artikel lesen | |
| 08:42 | RBC stuft ROCHE HOLDINGS AG auf 'Outperform' | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Roche auf "Outperform" mit einem Kursziel von 400 Franken belassen. Trung Huynh sieht die überraschend frühe Zulassung von... ► Artikel lesen | |
| 08:25 | Q3 review: an extra dose of upside; chg.: Pentixapharm enrolment and expected Q2 2027 partnering offer re-rating ... | NuWays | Pentixapharm's Q3 update reinforces the BUY case ahead of PANDA's start and potential partnering in 2027. Regulatory preparations have advanced, new oncology data strengthen the opportunity beyond primary... ► Artikel lesen | |
| 09:06 | Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) | Business Wire | - TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG =880 mg/dL (=10 mmol/L) - - Approximately 700,000 people in the EU5 are estimated to have triglyceride... ► Artikel lesen |